Conserved valproic-acid-induced lipid droplet formation in Dictyostelium and human hepatocytes identifies structurally active compounds

DMM Disease Models and Mechanisms

Volumn 5, Issue 2, 2012, Pages 231-240

  Elphick, Lucy M ^a   Pawolleck, Nadine ^a   Guschina, Irina A ^b   Chaieb, Leila ^a   Eikel, Daniel ^c   Nau, Heinz ^c   Harwood, John L ^b   Plant, Nick J ^d   Williams, Robin S B ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^d UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; FAT DROPLET; INOSITOL; PALMITIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; TRITIUM; VALPROIC ACID;

ARTICLE; DICTYOSTELIUM DISCOIDEUM; DRUG MECHANISM; FATTY ACID OXIDATION; LIPID STORAGE; LIVER CELL; LIVER CELL DAMAGE; NONHUMAN; PRIORITY JOURNAL; STEATOSIS; STRUCTURE ACTIVITY RELATION;

CELL LINE; DICTYOSTELIUM; FATTY ACIDS; FATTY LIVER; HEPATOCYTES; HUMANS; INOSITOL; KINETICS; LIPID METABOLISM; MODELS, BIOLOGICAL; SPECIES SPECIFICITY; TERATOGENS; VALPROIC ACID;

DICTYOSTELIUM; DICTYOSTELIUM DISCOIDEUM; MAMMALIA;

EID: 84863261732     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.008391     Document Type: Article

References (54)

1. Ackermann, E. J., Conde-Frieboes, K. and Dennis, E. A. (1995). Inhibition of macrophage Ca(2+)-independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones. J. Biol. Chem. 270, 445-450.
2. Adley, K., Keim, M. and Williams, R. S. B. (2005). Pharmacogenetics: defining the genetic basis of drug action and inositol trisphosphate analysis. In Methods in Molecular Biology: Dictyostelium discoideum (ed. L. Eichinger and F. Rivero), pp. 517-534. Totowa: The Humana Press.
3. Aires, C. C., van Cruchten, A., Ijlst, L., de Almeida, I. T., Duran, M., Wanders, R. J. and Silva, M. F. (2011). New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J. Hepatol. 55, 426-434.
4. Balsinde, J. and Dennis, E. A. (1996). Distinct roles in signal transduction for each of the phospholipase A2 enzymes present in P388D1 macrophages. J. Biol. Chem. 271, 6758-6765. (Pubitemid 26104108)
5. Basselin, M., Chang, L., Seemann, R., Bell, J. M. and Rapoport, S. I. (2003). Chronic lithium administration potentiates brain arachidonic acid signaling at rest and during cholinergic activation in awake rats. J. Neurochem. 85, 1553-1562. (Pubitemid 36702567)
6. Bauche, F., Sabourault, D., Giudicelli, Y., Nordmann, J. and Nordmann, R. (1983). Inhibition in vitro of acyl-CoA dehydrogenases by 2-mercaptoacetate in rat liver mitochondria. Biochem. J. 215, 457-464.
7. Bazan, N. G., Tu, B. and Rodriguez de Turco, E. B. (2002). What synaptic lipid signaling tells us about seizure-induced damage and epileptogenesis. Prog. Brain Res. 135, 175-185. (Pubitemid 35461016)
8. Bazinet, R. P., Rao, J. S., Chang, L., Rapoport, S. I. and Lee, H. J. (2005). Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder. Biol. Psychiatry 184, 122-129.
9. Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T. and White, H. S. (2010). Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 92, 89-124.
10. Boeckeler, K., Adley, K., Xu, X., Jenkins, A., Jin, T. and Williams, R. S. B. (2006). The neuroprotective agent, valproic acid, regulates the mitogen-activated protein kinase pathway through modulation of protein kinase A signalling in Dictyostelium discoideum. Eur. J. Cell Biol. 85, 1047-1057. (Pubitemid 44317602)
11. Bosetti, F., Weerasinghe, G. R., Rosenberger, T. A. and Rapoport, S. I. (2003). Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J. Neurochem. 85, 690-696. (Pubitemid 36531932)
12. Chang, M. C., Contreras, M. A., Rosenberger, T. A., Rintala, J. J., Bell, J. M. and Rapoport, S. I. (2001). Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J. Neurochem. 77, 796-803. (Pubitemid 32466776)
13. Chang, P., Orabi, B., Deranieh, R. M., Dham, M., Hoeller, O., Shimshoni, J. A., Yagen, B., Bialer, M., Greenberg, M. L., Walker, M. C. et al. (2012). The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium. Dis. Model. Mech. 5, 115-124.
14. Drancourt, M., Bollet, C., Carta, A. and Rousselier, P. (2001). Phylogenetic analyses of Klebsiella species delineate Klebsiella and Raoultella gen. nov., with description of Raoultella ornithinolytica comb. nov., Raoultella terrigena comb. nov. and Raoultella planticola comb. nov. Int. J. Syst. Evol. Microbiol. 51, 925-932. (Pubitemid 32499296)
15. Eadie, M. J., Hooper, W. D. and Dickinson, R. G. (1988). Valproate-associated hepatotoxicity and its biochemical mechanisms. Med. Toxicol. Adverse Drug Exp. 3, 85- 106.
16. Eickholt, B. J., Towers, G., Ryves, W. J., Eikel, D., Adley, K., Ylinen, L., Chadborn, N., Harwood, A., Nau, H. and Williams, R. S. B. (2005). Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, GSK-3b inhibition and viral replication-A screening approach for new bipolar disorder drugs based on the valproic acid core structure. Mol. Pharmacol. 67, 1-8.
17. Eikel, D., Lampen, A. and Nau, H. (2006). Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem. Res. Toxicol. 19, 272-278.
18. Eyal, S., Yagen, B., Shimshoni, J. and Bialer, M. (2005). Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochem. Pharmacol. 69, 1501-1508. (Pubitemid 40602450)
19. Fujimura, H., Murakami, N., Kurabe, M. and Toriumi, W. (2009). In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis. J. Appl. Toxicol. 29, 356-363.
20. Garbus, J., Deluca, H. F., Loomans, M. E. and Strong, F. M. (1963). The rapid incorporation of phosphate into mitochondrial lipids. J. Biol. Chem. 238, 59-63.
21. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Lo Coco. F., Nervi, C., Pelicci, P. G. et al. (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978. (Pubitemid 34062289)
22. Kalantari, F., Bergeron, J. J. and Nilsson, T. (2010). Biogenesis of lipid droplets-how cells get fatter. Mol. Membr. Biol. 27, 462-468.
23. Lagace, D. C., O'Brien, W. T., Gurvich, N., Nachtigal, M. W. and Klein, P. S. (2005). Valproic acid: how it works. Or not. Clin. Neurosci. Res. 4, 215-225.
24. 2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Biochim. Biophys. Acta. 1302, 55-60.
25. Ludtmann, M. H., Boeckeler, K. and Williams, R. S. B. (2011). Molecular pharmacology in a simple model system: Implicating MAP kinase and phosphoinositide signalling in bipolar disorder. Semin. Cell Dev. Biol. 22, 105-113.
26. Luef, G., Rauchenzauner, M., Waldmann, M., Sturm, W., Sandhofer, A., Seppi, K., Trinka, E., Unterberger, I., Ebenbichler, C. F., Joannidis, M. et al. (2009). Nonalcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res. 86, 42-47.
27. Masuccio, F., Verrotti, A., Chiavaroli, V., de Giorgis, T., Giannini, C., Chiarelli, F. and Mohn, A. (2010). Weight gain and insulin resistance in children treated with valproate: the influence of time. J. Child Neurol. 25, 941-947.
28. Melegh, B. and Trombitas, K. (1997). Valproate treatment induces lipid globule accumulation with ultrastructural abnormalities of mitochondria in skeletal muscle. Neuropediatrics 28, 257-261. (Pubitemid 27487733)
29. Meunier, H., Carraz, G., Neunier, Y., Eymard, P. and Aimard, M. (1963). Pharmacodynamic properties of N-dipropylacetic acid. Therapie 18, 435-438.
30. Mitchell, S., Poyser, N. L. and Wilson, N. H. (1977). Effect of p-bromophenacyl bromide, an inhibitor of phospholipase A2, on arachidonic acid release and prostaglandin synthesis by the guinea-pig uterus in vitro. Br. J. Pharmacol. 59, 107- 113.
31. Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T. and Sato, J. (1982). Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 42, 3858-3863. (Pubitemid 12054507)
32. Pawolleck, N. and Williams, R. S. B. (2009). Quantifying in vivo phosphoinositide turnover in chemotactically competent Dictyostelium cells. Methods Mol. Biol. 571, 283-290.
33. Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A. and Klein, P. S. (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36734-36741.
34. Rapoport, S. I. (2008). Arachidonic acid and the brain. J. Nutr. 138, 2515-2520.
35. Rapoport, S. I. and Bosetti, F. (2002). Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch. Gen. Psychiatry 59, 592-596. (Pubitemid 34747238)
36. Riebeling, C., Pirow, R., Becker, K., Buesen, R., Eikel, D., Kaltenhauser, J., Meyer, F., Nau, H., Slawik, B., Visan, A. et al. (2011). The embryonic stem cell test as tool to assess structure-dependent teratogenicity: the case of valproic acid. Toxicol. Sci. 120, 360-370.
37. Rintala, J., Seemann, R., Chandrasekaran, K., Rosenberger, T. A., Chang, L., Contreras, M. A., Rapoport, S. I. and Chang, M. C. (1999). 85 kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain. Neuroreport 10, 3887- 3890.
38. Schaloske, R. H., Blaesius, D., Schlatterer, C. and Lusche, D. F. (2007). Arachidonic acid is a chemoattractant for Dictyostelium discoideum cells. J. Biosci. 32, 1281-1289.
39. Shimshoni, J. A., Dalton, E. C., Jenkins, A., Eyal, S., Kwan, K., Williams, R. S., Pessah, N., Yagen, B., Harwood, A. J. and Bialer, M. (2007). The effects of CNSactive Valproic acid constitutional isomers, cyclopropyl analogues and amide derivatives on neuronal growth cone behaviour. Mol. Pharmacol. 71, 884-892. (Pubitemid 46294100)
40. Silva, M. F., Aires, C. C., Luis, P. B., Ruiter, J. P., Ijlst, L., Duran, M., Wanders, R. J. and Tavares de Almeida, I. (2008). Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review. J. Inherit. Metab. Dis. 31, 205-216.
41. Spiegelstein, O., Kroetz, D. L., Levy, R. H., Yagen, B., Hurst, S. I., Levi, M., Haj-Yehia, A. and Bialer, M. (2000). Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid. Pharm. Res. 17, 216-221. (Pubitemid 30158372)
42. Stephens, J. R. and Levy, R. H. (1992). Valproate hepatotoxicity syndrome: hypotheses of pathogenesis. Pharm. Weekbl. Sci. 14, 118-121.
43. Svennerholm, L. (1968). Distribution and fatty acid composition of phosphoglycerides in normal human brain. J. Lipid Res. 9, 570-579.
44. Terbach, N. and Williams, R. S. (2009). Structure-function studies for the panacea, valproic acid. Biochem. Soc. Trans. 37, 1126-1132.
45. Terbach, N., Shah, R., Kelemen, R., Klein, P. S., Gordienko, D., Brown, N. A., Wilkinson, C. J. and Williams, R. S. B. (2011). Identifying an uptake mechanism for the antiepileptic and bipolar disorder treatment valproic acid using the simple biomedical model Dictyostelium. J. Cell Sci. 124, 2267-2276.
46. Verrotti, A., Agostinelli, S., Parisi, P., Chiarelli, F. and Coppola, G. (2011a). Nonalcoholic fatty liver disease in adolescents receiving valproic acid. Epilepsy Behav. 20, 382-385.
47. Verrotti, A., D'Egidio, C., Mohn, A., Coppola, G. and Chiarelli, F. (2011b). Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes. Rev. 12, e32-e43.
48. von Lohneysen, K., Pawolleck, N., Ruhling, H. and Maniak, M. (2003). A Dictyostelium long chain fatty acyl coenzyme A-synthetase mediates fatty acid retrieval from endosomes. Eur. J. Cell Biol. 82, 505-514. (Pubitemid 37428296)
49. Weeks, G. (1976). The manipulation of the fatty acid composition of Dictyostelium discoideum and its effect on cell differentiation. Biochim. Biophys. Acta 450, 21- 32.
50. Williams, R. S. B. (2005). Pharmacogenetics in model systems: Defining a common mechanism of action for mood stabilisers. Progress in Neuro-psychopharmacology and Biological Psychiatry 29, 1029-1037.
51. Williams, R. S. B., Cheng, L., Mudge, A. W. and Harwood, A. J. (2002). A common mechanism of action for three mood-stabilizing drugs. Nature 417, 292-295. (Pubitemid 34534711)
52. Wirrell, E. C. (2003). Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr. Neurol. 28, 126-129.
53. Worsfold, O., Toma, C. and Nishiya, T. (2004). Development of a novel optical bionanosensor. Biosens. Bioelectron. 19, 1505-1511. (Pubitemid 38456922)
54. Xu, X., Muller-Taubenberger, A., Adley, K. E., Pawolleck, N., Lee, V. W., Wiedemann, C., Sihra, T. S., Maniak, M., Jin, T. and Williams, R. S. (2007). Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid. Eukaryot. Cell 6, 899-906. (Pubitemid 46983290)